波斯药物配方Glasthma对喘患者的肺功能和肠道透性的影响:一项三盲随机对照试验
Ali Reza Derakhshan1,2, Majid Mirsadraee3, Amirhashem Asnaashari4
1Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences. Mashhad, Iran.
Avicenna journal of phytomedicine
|September 19, 2025
概括
波斯草药Glasthma显著改善了患者的喘控制和肺功能. 这种天然配方还显示出调节肠肺轴的潜力,为喘管理提供了一种新的方法.
科学领域:
- 综合医学是一个整体的医学.
- 呼吸系统医学 呼吸系统医学
- 胃肠病学 胃肠病学
背景情况:
- 喘是一种慢性呼吸道疾病,对生活质量产生重大影响.
- 肠道透性,或肠肺轴,越来越多地被认为是喘发病的一个因素.
- 传统波斯医学为慢性疾病提供了潜在的治疗途径.
研究的目的:
- 评估Glasthma的疗效和安全性,这是一个波斯草药配方,用于控制喘症状.
- 评估Glasthma对喘患者肠道透性的影响.
- 探索由Glasthma调节肠肺轴的情况.
主要方法:
- 一个随机的,安慰剂对照试验,涉及40名喘患者.
- 参与者每天两次接受Glasthma糖或安慰剂,持续4周.
- 评估包括呼吸道症状得分,肺功能测试和乳糖与曼尼托尔的比率.
主要成果:
- 与安慰剂相比,Glasthma组在喘控制测试 (ACT,ACQ-7) 和肺功能 (FEV1,MEF 25-75) 中显著改善.
- 在Glasthma组中观察到尿液中乳糖和曼尼托尔水平的显著降低.
- 没有报告严重的不良影响,这表明安全性概况有利.
结论:
- 格拉斯玛配方在改善喘症状和肺功能方面表现出显著的有效性.
- 草药配方可以通过调节肠道透性来积极影响肠肺轴.
- 喘代表了喘管理的有前途的自然治疗方案.
相关概念视频
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-III: Symptoms and Complications
3.3K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.3K
Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Antiasthma Drugs: Methylxanthines
1.6K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.6K


